Full-Time

MERA Tender and Contracting Lead

Tender Management

Posted on 9/23/2025

Deadline 10/3/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

No salary listed

Madrid, Spain

In Person

Job is based in MERA (outside UAE & Saudi) with specific focus on Turkey and Spain.

Category
Business & Strategy (2)
,
Required Skills
Marketing
Data Analysis
Requirements
  • Bachelor’s degree in pharmacy, Business Administration, Marketing, Economics, or a related discipline. Master’s degree is a plus.
  • At least 15 years of progressive experience in the pharmaceutical industry, with a minimum of 10 years of managerial roles overseeing public channel including tendering, sales, marketing, market access, pricing, category leadership or other relevant roles.
  • Deep understanding of public tendering frameworks, contracting mechanisms, financing models, and regulatory environments of different markets, preferably within MERA.
  • Proven experience in developing and executing commercial and access strategies across multiple markets and different Therapy Areas.
  • Diverse leadership experiences of cross-functional collaboration, coaching and team oversight to drive impactful business outcomes.
  • Strong organizational skills with the ability to prioritize competing demands and managing complex projects in a matrixed organization.
  • Champion innovation by proactively challenging the status quo and fostering an entrepreneurial mindset.
  • Translate strategic objectives into actionable plans with a strong focus on quality, performance, and results.
  • Build and maintain strong relationships through exceptional interpersonal, communication, and stakeholder engagement skills across diverse geographies and functions.
Responsibilities
  • Drive proactive planning and execution of tender and contracting activities across MERA geographies, ensuring alignment with cross-functional stakeholders and business priorities.
  • Develop efficient information management systems to enable forward-looking visibility into key tenders across the region, including tracking performance and reporting outcomes.
  • Perform in-depth and predictive analysis of tenders to segment bidding strategies. Identify high-impact tenders in operating plans, define Must-Win Tenders (MWTs), assess risks, and support the development of strategic bidding plans.
  • Analyze other bidders’ strategies and provide proactive support to country teams to enhance the competitiveness and effectiveness of tender submissions.
  • Create and maintain a centralized competitive insight cockpit to support regional and country leadership with real-time data and strategic insights.
  • Evaluate and prioritize tenders and supply needs across countries, ensuring adherence to global pricing guidelines and supporting consistent product availability.
  • Provide regional stakeholders with actionable insights into the key tenders to maintain supply continuity and optimize cost of goods sold (CoGS) through volume efficiencies.
  • Identification of White Space - Develop strategies to win previously lost tenders, uncover untapped opportunities, and optimize the portfolio to grow underutilized brands and SKUs.
  • Maximize top-line revenue and improve margins in the tender business by identifying growth drivers and delivering strategic recommendations to Country Presidents and Managers.
  • Oversee the end-to-end tender management lifecycle, ensuring strategic alignment, operational excellence, and continuous improvement.
  • Advance and manage a comprehensive regional database encompassing tender calendars, must-win tenders (MWTs), risk and opportunity assessments, and required support actions to capitalize on strategic opportunities and mitigate risks.
  • Support the development and implementation of forward-thinking tender strategies aimed at accelerating product access across tender channels, including exploring value-based agreements in alignment with regional and global stakeholders.
  • Drive proactive readiness for key tenders through early planning and preparation ahead of tender openings, particularly on GTCs, to ensure timely and high-quality submissions.
  • Guide and support the development of tender pricing strategies and bidding approaches, ensuring full compliance with global pricing guidance and alignment with regional objectives.
  • Provide direct support for the submission of must-win tenders, coordinating closely with regional and affiliate teams to ensure strategic alignment and execution excellence.
  • Offer expert guidance and analytical support throughout the tender lifecycle—from documentation preparation to contract award—ensuring consistency, compliance, and competitiveness.
  • Build and maintain strong internal partnerships with key stakeholders across Global, Regional, and Local teams—including GAV, NIP, PGS, ICO, Country Managers/Presidents, Legal, Compliance, Medical, and local tender teams—to collaboratively address tender and contracting challenges and ensure seamless execution.
  • Partner with regional stakeholders to co-lead global initiatives focused on allocation optimization and enterprise margin acceleration, ensuring alignment with broader organizational goals and driving sustainable business impact across MERA.
  • Identify and manage risks associated with tender and contracting activities, integrating risk assessments into business reviews. Support the pilot of new concepts and approaches to enhance competitiveness and operational resilience.
  • Align projects objectives and activities with regional partners to ensure seamless integration with broader initiatives, maximizing impact and resource utilization.
  • Provide strategic input into the annual planning process by coordinating with regional and global stakeholders to manage tender-related analysis, reporting, and target setting for budget development and review.
  • Drive consistency in value proposition, differentiation, pricing, and commercial conditions across countries and tender opportunities to reinforce strategic positioning and brand equity.
  • Analyze customer requirements and dissect bid specifications to support the design of tailored solutions, including strategic wording, documentation, and presentation materials.
  • Lead early planning and strategic shaping of key tenders by coordinating cross-functional input—including Public Affairs, Policy, and Medical—to ensure differentiated, competitive, and locally relevant bid positioning.
  • Advocate the development of localized Bid Value Matrices and communication plans, as permissible, for priority tenders, ensuring alignment with affiliate teams and responsiveness to market-specific dynamics.
  • Advocate the identification of key institutional customers and stakeholders and support the development of comprehensive stakeholder mapping and engagement strategies to appropriately position our innovations.
  • Identify and address technology and capability gaps by integrating global Tender & Contracting platforms and tools to enhance operational efficiency and data-driven decision-making.
  • Design and implement robust dashboards and KPIs to monitor and assess tender and contracting operations across the region, enabling data-driven decision-making and continuous improvement.
  • In collaboration with ICO Tender & Contracting, lead high-impact training programs for regional and local teams. Establish and support a network of tender champions across countries to foster best practices and elevate tendering capabilities.
Desired Qualifications
  • Master’s degree is a plus.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Berobenatide could create a differentiated obesity franchise if Phase 3 succeeds.
  • The 25-valent pneumococcal vaccine can extend Pfizer's vaccine leadership beyond Prevnar.
  • AI licensing with Chai Discovery may accelerate early-stage drug design and hit rates.

What critics are saying

  • Eliquis, Ibrance, and Xtandi patent expirations will pressure revenue before replacements mature.
  • Berobenatide faces entrenched GLP-1 competition and a costly 10-plus-trial Phase 3 program.
  • Pfizer's oncology strategy depends on late-stage execution across dozens of programs and partnerships.

What makes Pfizer unique

  • Pfizer directs about 40% of R&D into oncology across five tumor areas.
  • Its oncology pipeline spans 50+ programs, 25+ new molecular entities, and 3 modalities.
  • HYMPAVZI is the first subcutaneous non-factor therapy for pediatric hemophilia B ages 6-11.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Pfizer who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

2%
Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE